{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T09:06:36Z","timestamp":1789031196484,"version":"build-2803163510"},"reference-count":9,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2027,9,3]],"date-time":"2027-09-03T00:00:00Z","timestamp":1819929600000},"content-version":"am","delay-in-days":367,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000065","name":"National Institute of Neurological Disorders and Stroke","doi-asserted-by":"publisher","award":["NS125318"],"award-info":[{"award-number":["NS125318"]}],"id":[{"id":"10.13039\/100000065","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000065","name":"National Institute of Neurological Disorders and Stroke","doi-asserted-by":"publisher","award":["NS115403"],"award-info":[{"award-number":["NS115403"]}],"id":[{"id":"10.13039\/100000065","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000065","name":"National Institute of Neurological Disorders and Stroke","doi-asserted-by":"publisher","award":["NS133160"],"award-info":[{"award-number":["NS133160"]}],"id":[{"id":"10.13039\/100000065","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Trends in Pharmacological Sciences"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.tips.2026.07.010","type":"journal-article","created":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T04:31:35Z","timestamp":1786941095000},"page":"952-954","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Sequential EGFR inhibition sensitizes glioblastoma to temozolomide"],"prefix":"10.1016","volume":"47","author":[{"given":"Xiaozhou","family":"Yu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Runxin","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1737-0588","authenticated-orcid":false,"given":"Shi-Yuan","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.tips.2026.07.010_bb0005","doi-asserted-by":"crossref","first-page":"2751","DOI":"10.1093\/neuonc\/noaf177","article-title":"Glioblastoma in adults: a Society for Neuro-Oncology (SNO) and European Society of Neuro-Oncology (EANO) consensus review on current management and future directions","volume":"27","author":"Wen","year":"2025","journal-title":"Neuro Oncol."},{"key":"10.1016\/j.tips.2026.07.010_bb0010","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1016\/j.trecan.2025.01.007","article-title":"Regulated cell death modalities: breaking resistance of temozolomide glioblastoma therapy","volume":"11","author":"Mishchenko","year":"2025","journal-title":"Trends Cancer"},{"key":"10.1016\/j.tips.2026.07.010_bb0015","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1038\/nrneurol.2014.100","article-title":"MGMT testing\u2014the challenges for biomarker-based glioma treatment","volume":"10","author":"Wick","year":"2014","journal-title":"Nat. Rev. Neurol."},{"key":"10.1016\/j.tips.2026.07.010_bb0020","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.adx8398","article-title":"EGFR inhibition down-regulates MGMT and enhances responsiveness to temozolomide in glioblastoma","volume":"18","author":"Nayab","year":"2026","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.tips.2026.07.010_bb0025","first-page":"430","article-title":"Phase I\/randomized phase II study of afatinib, an irreversible ErbB family blocker, with or without protracted temozolomide in adults with recurrent glioblastoma","volume":"17","author":"Reardon","year":"2015","journal-title":"Neuro Oncol."},{"key":"10.1016\/j.tips.2026.07.010_bb0030","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1016\/j.cell.2013.09.034","article-title":"The somatic genomic landscape of glioblastoma","volume":"155","author":"Brennan","year":"2013","journal-title":"Cell"},{"key":"10.1016\/j.tips.2026.07.010_bb0035","doi-asserted-by":"crossref","first-page":"viii14","DOI":"10.1093\/neuonc\/nou222","article-title":"Challenges to targeting epidermal growth factor receptor in glioblastoma: escape mechanisms and combinatorial treatment strategies","volume":"16","author":"Roth","year":"2014","journal-title":"Neuro Oncol."},{"key":"10.1016\/j.tips.2026.07.010_bb0040","doi-asserted-by":"crossref","first-page":"2035","DOI":"10.1093\/neuonc\/noac204","article-title":"EGFR, the Lazarus target for precision oncology in glioblastoma","volume":"24","author":"Lin","year":"2022","journal-title":"Neuro Oncol."},{"key":"10.1016\/j.tips.2026.07.010_bb0045","doi-asserted-by":"crossref","first-page":"5080","DOI":"10.1200\/JCO.2008.21.5541","article-title":"Randomized, placebo-controlled, phase II study of sequential erlotinib and chemotherapy as first-line treatment for advanced non-small-cell lung cancer","volume":"27","author":"Mok","year":"2009","journal-title":"J. Clin. Oncol."}],"container-title":["Trends in Pharmacological Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165614726001975?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165614726001975?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T08:11:34Z","timestamp":1789027894000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0165614726001975"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":9,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["S0165614726001975"],"URL":"https:\/\/doi.org\/10.1016\/j.tips.2026.07.010","relation":{},"ISSN":["0165-6147"],"issn-type":[{"value":"0165-6147","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Sequential EGFR inhibition sensitizes glioblastoma to temozolomide","name":"articletitle","label":"Article Title"},{"value":"Trends in Pharmacological Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.tips.2026.07.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}